MAPT and Alzheimer disease: In order for structure-based drug discovery efforts for AD to be as successful as efforts in other diseases, disaggregants identified as drug leads must be free of toxicity at effective concentrations and must produce products of disaggregation that are not toxic and which do not seed monomeric tau into amyloid fibrils.